

PRESS RELEASE | ECULLY, FRANCE – February 17, 2025

## **SEQENS and APPLEXION announce strategic partnership for the distribution of SEQENZYM FT, a processing aid enzyme for the food market.**

The SEQENS Group, a global partner in health, personal care and specialty ingredients, is excited to announce a strategic partnership with APPLEXION, a historic & global supplier of purification technologies. SEQENS\*, through Protéus, has developed a long-standing expertise in enzyme discovery, optimization, and biocatalytic process implementation, while APPLEXION is a world-class leader in developing, designing, supplying, and installing purification technology-based processes and industrial units across various markets.

This collaboration expands APPLEXION's catalog of consumables by appointing them as the exclusive distributor of SEQENZYM FT, an innovative enzymatic solution developed by SEQENS, in the specific market segment of agro-food industry. SEQENZYM FT has received the self-GRAS status in the USA based on evaluation by independent expert's panelists and is believed to be among the leading enzymes on the market that demonstrate only fructosyl-transferase activity, efficiently converting sucrose into short-chain fructo-oligosaccharides (scFOS). SEQENZYM FT shows higher yield, lower free fructose and no color formation, compared to existing enzymes that may exhibit deleterious invertase activity.

Looking ahead, SEQENS and APPLEXION have committed to jointly develop new enzymes to serve as processing aids in the food industry, leveraging their combined expertise to drive innovation and enhance product offerings.

*"By combining our strengths with APPLEXION, we are well-positioned to significantly impact the food processing aids enzyme industry by delivering unmatched solutions that meet the evolving needs of our customers"* says Julien Boutet, Innovation & Biotechnologies Director at SEQENS.

*"SEQENS and APPLEXION technologies are a perfect match to ensure robust production of prebiotics with higher yield and purity. APPLEXION digital services support these synergies for a day-to-day efficient production."* says Damien Brichant, President of APPLEXION.

### **About SEQENS:**

SEQENS is a global partner in health, personal care and specialty ingredients, leveraging 3300 employees, 16 manufacturing sites and 9 R&D centers in 9 countries. As an integrated player across the entire value chain - from raw materials to active ingredients and from R&D to industrialization - SEQENS offers a broad portfolio of active pharmaceutical ingredients, pharmaceutical intermediates and specialty ingredients, develops and industrializes the most complex molecules, and leverages its ability to innovate, develop and implement the best available technologies. Driven by a culture of excellence and a strong entrepreneurial spirit, the group shares values such as unity, agility, and reactivity. SEQENS provides the highest level of service and quality to more than 1500 customers around the world while acting ethically in accordance with its strong CSR program.

\* SEQENS refers to the legal entity PCAS SAS  
press@seqens.com / [www.seqens.com](http://www.seqens.com) / LinkedIn : SEQENS

### **About APPLEXION:**

Applexion is an historic & global supplier of purification technologies such as chromatography, ion exchange and ceramic membrane filtration. For the last years, it has designed, built, and commissioned more than 800 units all over the world. The company is internationally recognized for its first-class services and consumables reliable supply, covering every step of the value chain in the life cycle of each production equipment. With headquarters based at Saint-Maurice de Beynost (near Lyon, France) and a strong international presence. Applexion employs 150 people.

[contactus@applexion.com](mailto:contactus@applexion.com) / [www.applexion.com](http://www.applexion.com) / LinkedIn : APPLEXION

[www.seqens.com](http://www.seqens.com)

SEQENS SAS - 21 chemin de la Sauvegarde, 21 Ecully Parc - CS 33167 - 69134 ECULLY Cedex - Capital Social 226 890 746.63 euros - 444 465 736 00049  
RCS Lyon - Tel : +33 (0)4 26 99 18 00 - Fax : +33 (0)4 26 99 18 38